Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of datopotamab deruxtecan alone and in combination for advanced or metastatic solid tumors
CTR20222821Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2023; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222821.